Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Merrimack Pharmaceuticals","sponsor":"Ipsen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merrimack Provides Ipsen Report of Results From Phase III RESILIENT Trial Evaluating Onivyde\u00ae in Second-Line Monotherapy for Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Merrimack Pharmaceuticals","sponsor":"Ipsen","pharmaFlowCategory":"D","amount":"$1,025.0 million","upfrontCash":"$575.0 million","newsHeadline":"Merrimack Receives $225 Million Milestone Payment from Ipsen","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Merrimack Pharmaceuticals

    Menu

    Merrimack Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Merrimack Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Merrimack Receives $225 Million Milestone Payment from Ipsen

              Details:

              Ipsen acquired exclusive commercialization rights for the current and potential future Onivyde, a unique encapsulation formulation of irinotecan in a long-circulating liposomal, as a first-line treatment of metastatic adenocarcinoma on the pancreas in the US.

              Lead Product(s): Irinotecan Hydrochloride,Fluorouracil,Calcium Folinate

              Therapeutic Area: Oncology Product Name: Onivyde

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Ipsen

              Deal Size: $1,025.0 million Upfront Cash: $575.0 million

              Deal Type: Acquisition March 27, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Merrimack Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Merrimack Provides Ipsen Report of Results From Phase III RESILIENT Trial Evaluating Onivyde® in Second-Line Monotherapy for Small Cell Lung Cancer

              Details:

              The press release indicates that the “the primary endpoint OS was not met in patients treated with Onivyde (irinotecan) versus topotecan. However, a doubling of the secondary endpoint of objective response rate (ORR) in favor of Onivyde was observed.

              Lead Product(s): Irinotecan Hydrochloride

              Therapeutic Area: Oncology Product Name: Onivyde

              Highest Development Status: Phase III Product Type: Small molecule

              Recipient: Ipsen

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 03, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.
              Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.
              Post Enquiry
              POST ENQUIRY